Get the Stockscreener App
45.84
0.80%
0.425
Royalty Pharma Plc stock is traded at $45.84, with a volume of 2.47M.
It is up +0.80% in the last 24 hours and up +3.92% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$45.41
Open:
$45.41
24h Volume:
2.47M
Relative Volume:
0.66
Market Cap:
$19.60B
Revenue:
$2.35B
Net Income/Loss:
$1.30B
P/E Ratio:
26.21
EPS:
1.7487
Net Cash Flow:
$1.05B
1W Performance:
-3.57%
1M Performance:
+3.92%
6M Performance:
+25.41%
1Y Performance:
+38.67%
1-Day Range:
$45.27
$45.94
1-Week Range:
$44.94
$47.86
52-Week Range:
$29.66
$47.86
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
45.74 | 19.45B | 2.35B | 1.30B | 1.05B | 1.7487 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.76 | 116.01B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.92 | 80.33B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
740.38 | 44.42B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.40 | 42.53B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
302.08 | 33.32B | 5.36B | 287.73M | 924.18M | 2.5229 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | UBS | Neutral → Buy |
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Royalty Pharma PLC $RPRX is Regal Partners Ltd's 10th Largest Position - MarketBeat
Royalty Pharma PLC $RPRX Stock Position Decreased by Rhenman & Partners Asset Management AB - MarketBeat
Neo Ivy Capital Management Buys New Position in Royalty Pharma PLC $RPRX - MarketBeat
Goodman Advisory Group LLC Purchases New Stake in Royalty Pharma PLC $RPRX - MarketBeat
CM Management LLC Takes $1.76 Million Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Plc Hits New 52-Week High of USD 47.86 - Markets Mojo
Vera Therapeutics Appoints Christopher Hite to Board of Directors - GlobeNewswire Inc.
Royalty Pharma (NASDAQ:RPRX) Reaches New 12-Month HighStill a Buy? - MarketBeat
Royalty Pharma Plc Hits New 52-Week High of USD 47.66 - Markets Mojo
Royalty Pharma (NASDAQ:RPRX) CFO Terrance Coyne Sells 34,791 Shares - MarketBeat
Insider sales of common stock — Repare Therapeutics (NASDAQ: RPRX) - Stock Titan
RPRX SEC FilingsRoyalty Pharma Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Victory Capital Management Inc. Purchases 165,727 Shares of Royalty Pharma PLC $RPRX - MarketBeat
RPRX Earnings History & Surprises | EPS & Revenue Results | ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) - ChartMill
A Look At Royalty Pharma (RPRX) Valuation After Robust 2025 Results And Expansion Plans In Asia - Sahm
Royalty Pharma at TD Cowen Conference: Strategic Growth Insights - Investing.com Nigeria
Royalty Pharma plc (RPRX) Earns $51 Target as 2026 Growth Outlook Exceeds Expectations - Yahoo Finance
RPRX Technical Analysis & ETF Price Forecast - Intellectia AI
Royalty Pharma (RPRX) Passes Through 2% Yield Mark - Nasdaq
Royalty Pharma Plc Hits New 52-Week High of USD 46.37 - Markets Mojo
TD Asset Management Inc Acquires 91,136 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Quantbot Technologies LP Makes New $2.82 Million Investment in Royalty Pharma PLC $RPRX - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Buys 44,289 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX) Achieves Record Growth and Hits Investment Targets Ahead of Schedule - Finviz
Zymeworks secures $250M royalty financing from Royalty Pharma - Investing.com South Africa
Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform - Utusan Malaysia
Royalty Pharma Appoints Kenneth Sun as Senior VP and Head of Asia - National Today
Affiliated holders sell large RPRX stakes (RPRX) in Feb 2026 trades - Stock Titan
Royalty Pharma Plc (RPRX): Investor Outlook With 11.57% Upside Potential - DirectorsTalk Interviews
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing - citybiz
Zymeworks Q4 Earnings Call Highlights - Yahoo Finance
Royalty Pharma PLC (NASDAQ:RPRX) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Royalty Pharma appoints Kenneth Sun to lead Asia expansion - Investing.com
Royalty Pharma appoints Kenneth Sun to lead Asia expansion By Investing.com - Investing.com Canada
Royalty Pharma Appoints Kenneth Sun as Senior Vice President - citybiz
Royalty Pharma plc Appoints Kenneth Sun as Senior Vice President and Head of Asia, Effective May 2026 - marketscreener.com
Zymeworks Secures $250 Mln Royalty Funding Deal With Royalty Pharma - Nasdaq
$250M cancer drug royalty deal extends Zymeworks’ cash runway - Stock Titan
Citigroup Inc. Trims Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Plc Hits New 52-Week High at $47.50 - Markets Mojo
RPRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TD Cowen Lifts PT on Royalty Pharma Plc (RPRX) to $50 from $45, Here's Why - Finviz
TD Cowen Lifts PT on Royalty Pharma Plc (RPRX) to $50 from $45, Here’s Why - Insider Monkey
12 Cheap Biotech Stocks to Buy Now - Insider Monkey
Royalty Pharma stock hits 52-week high at 46.14 USD By Investing.com - Investing.com Australia
Cowen Maintains Buy on Royalty Pharma plc (RPRX) Feb 27, 2026 - Meyka
TD Cowen raises Royalty Pharma stock price target to $50 on growth - Investing.com UK
Royalty Pharma (NASDAQ:RPRX) Sets New 52-Week HighWhat's Next? - MarketBeat
Royalty Pharma (RPRX) PT Raised to $50 at TD Cowen - StreetInsider
Royalty Pharma stock hits 52-week high at 46.14 USD - Investing.com South Africa
Royalty Pharma PLC $RPRX Shares Sold by Vanguard Group Inc. - MarketBeat
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):